Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
21 Things You Ought to Never Share with Your Childless Companion - 2New science points to 4 distinct types of autism
- 3Displaced Palestinian families suffer as heavy rains flood Gaza tent camps
- 4Japan prepares to restart world's biggest nuclear plant, 15 years after Fukushima
- 5A Manual for SUVs with Less Noteworthy Gas Mileage
- Mountain Trekking on a Tight spending plan: Tracking down the Right Bicycle
- Winter storm headed for Midwest to Northeast. Here's how much snow to expect.
- Which camera do you believe is great for first-time clients? !
- A definitive Manual for Internet Mastering and Expertise Improvement
- Doomed SpaceX Starlink satellite photographed from orbit
- Game theory explains why reasonable parents make vaccine choices that fuel outbreaks
- Poland Crypto Bill Clears Sejm Again, Defying President — Will “Restrictive” Rules Stick?
- Baby takes 1st steps after receiving groundbreaking gene-edited therapy
- 5 Morning Schedules That Stimulate Your Day
